Clinical Trials List
Protocol NumberNBM-BMX-002
NCT Number(ClinicalTrials.gov Identfier)NCT03808870
2019-02-01 - 2020-12-31
Phase I
Recruiting2
A Phase 1, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetic and efficacy of NBM-BMX in subjects with advanced solid tumors
-
Trial Applicant
Efficient Pharma Management Corp.
-
Sponsor
NatureWise Biotech & Medicals Corporation
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Ming-Huang Chen Division of Hematology & Oncology
- Yee Chao Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
1 Recruiting
Audit
None
Co-Principal Investigator
- Wen-Pin Su Division of Hematology & Oncology
- Chia-Jui Yen Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
4 Recruiting
Audit
None
Condition/Disease
Malignant Neoplasm
Objectives
The objectives of this study are to determine the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).
Test Drug
NBM-BMX
Active Ingredient
NBM-BMX
Dosage Form
softgel capsule
Dosage
50 or 75
Endpoints
Primary Outcome Measures:
1. Dose limiting toxicity (DLT) of NBM-BMX.
2. Maximum tolerated dose (MTD) of NBM-BMX.
Secondary Outcome Measures:
1. Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) [Efficacy].
2. AUC(0-last) of NBM-BMX [Pharmacokinetics].
3. Cmax of NBM-BMX [Pharmacokinetics].
4. Tmax of NBM-BMX [Pharmacokinetics].
5. T(1/2) of NBM-BMX [Pharmacokinetics].
1. Dose limiting toxicity (DLT) of NBM-BMX.
2. Maximum tolerated dose (MTD) of NBM-BMX.
Secondary Outcome Measures:
1. Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) [Efficacy].
2. AUC(0-last) of NBM-BMX [Pharmacokinetics].
3. Cmax of NBM-BMX [Pharmacokinetics].
4. Tmax of NBM-BMX [Pharmacokinetics].
5. T(1/2) of NBM-BMX [Pharmacokinetics].
Inclution Criteria
1. Histologically or cytologically confirmed advanced, non-resectable, and/or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available, or who were not amenable to established forms of treatment.
2. Solid tumors must have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
3. Female or male at 20 years of age or older.
4. ECOG performance status 0 to 2.
5. Recovered from prior treatment-related toxicity to at least grade 1 with exception of grade 2 alopecia.
6. Adequate organ function as defined by the following criteria:
(1) Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤3 x upper limit of normal (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to underlying malignancy
(2) Total serum bilirubin ≤1.5 x ULN (except for subjects with documented Gilbert's syndrome)
(3) Absolute neutrophil count (ANC) ≥ 1500/µL
(4) Platelets ≥ 90,000/µL
(5) Hemoglobin ≥ 9.0 g/dL
(6) Serum creatinine ≤ 2.0 x ULN
7. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
2. Solid tumors must have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
3. Female or male at 20 years of age or older.
4. ECOG performance status 0 to 2.
5. Recovered from prior treatment-related toxicity to at least grade 1 with exception of grade 2 alopecia.
6. Adequate organ function as defined by the following criteria:
(1) Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤3 x upper limit of normal (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to underlying malignancy
(2) Total serum bilirubin ≤1.5 x ULN (except for subjects with documented Gilbert's syndrome)
(3) Absolute neutrophil count (ANC) ≥ 1500/µL
(4) Platelets ≥ 90,000/µL
(5) Hemoglobin ≥ 9.0 g/dL
(6) Serum creatinine ≤ 2.0 x ULN
7. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria
1. Major surgery or radiation therapy within 28 days of starting study treatment.
2. Systemic anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) of starting study treatment.
3. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
4. Current treatment on another clinical trial.
5. Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks.
6. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and medical monitor, the 6-month post-event-free period for a subject with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted.
7. NYHA Class III or IV heart failure and known history of QTc prolongation or Torsade de Pointes.
8. Use of medications known to significantly prolong the QTc interval (e.g., anti-arrhythmic and psychotropic medications).
9. Hypertension that cannot be controlled by medications.
10. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
11. Known human immunodeficiency virus (HIV)-positive and is receiving anti-retroviral therapy.
12. Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody).
13. History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy.
14. Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or medical monitor, excess risk associated with study participation or study drug administration, which would make the subject inappropriate for entry into this study.
2. Systemic anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) of starting study treatment.
3. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
4. Current treatment on another clinical trial.
5. Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks.
6. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and medical monitor, the 6-month post-event-free period for a subject with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted.
7. NYHA Class III or IV heart failure and known history of QTc prolongation or Torsade de Pointes.
8. Use of medications known to significantly prolong the QTc interval (e.g., anti-arrhythmic and psychotropic medications).
9. Hypertension that cannot be controlled by medications.
10. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
11. Known human immunodeficiency virus (HIV)-positive and is receiving anti-retroviral therapy.
12. Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody).
13. History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy.
14. Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or medical monitor, excess risk associated with study participation or study drug administration, which would make the subject inappropriate for entry into this study.
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
30 participants
